Nextleaf wins patent for THC-enhancing prodrug THC-O-Acetate

The company said THC-O-Acetate is capable of quadrupling the potency of THC

Cannabis leaves next to a bottle with an eye dropper overlayed with THC and CBD molecular structure
Nextleaf's latest patent describes a process for acetylating THC and refining it into THC-O-Acetate

Nextleaf Solutions Ltd (CSE:OILS) (OTCQB:OILFF) announced Wednesday that the Canadian Intellectual Property Office has granted the company a patent covering the creation of a THC prodrug, its 40th issued patent.

Specifically, the patent describes a process for acetylating (inserting an acetyl group into a compound) delta 9-tetrahydrocannabinol (THC) and refining it into THC-O-Acetate using salting-out assisted liquid-liquid extraction and distillation techniques.

THC-O-Acetate is prodrug, which can enhance the potency of THC.

READ: Nextleaf Solutions commercializing its intellectual property and scaling up biomass processing

"Nextleaf's patented process to produce THC-O-Acetate enables the standardization of a more potent analog of THC, an alternative option to experience the unique medicinal benefits, associated with targeted drug delivery," CEO Paul Pedersen said in a statement. "The potency of THC-O-Acetate is said to be 300% that of THC with potentially psychedelic features."

Nextleaf’s goal is to maintain the integrity of the molecule and its ability to deliver drugs to precisely targeted areas in order to significantly reduce consumption, as well as reduce unintended side effects.

"To the best of my knowledge, Nextleaf is the first company in the world, publicly traded or private, to be issued patents for the production of THC-O-Acetate in any jurisdiction, including the United States and Canada," Director of Intellectual Property Taran Grey said.

Nextleaf said it has a 100% success rate obtaining issued patents from its pending patent applications, compared to averages below 50% for life sciences companies. The Vancouver-based company expects opportunities to commercialize its latest patent through IP licensing agreements with pharmaceutical companies and by producing IP-protected cannabinoid products.

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel


Price: 0.36 CAD

Market: CSE
Market Cap: $43 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of NEXTLEAF SOLUTIONS Ltd. named herein, including the promotion by the Company of NEXTLEAF SOLUTIONS Ltd. in any Content on the Site, the Company...


Nextleaf Solutions Issued U.S. Patent and Launches CBD Oils

Nextleaf Solutions (CSE: OILS- OTCQB: OILFF) CEO Paul Pedersen joined Steve Darling from Proactive with news the U.S. Patent and Trademark Office has granted a patent for a process resulting in a solventless cannabis concentrate. Pedersen shares with Proactive what that process is for as the...

2 days, 3 hours ago

2 min read